In subsequent experiments, researchers discovered that blocking CPT1 using etomoxir, a specific inhibitor, disrupted the OXPHOS status and significantly potentiated the cytotoxic effect of Ara-C on drug-resistant leukemia cells (Salunkhe et al., 2020). This evidence concerns the gene CPT2 and leukemia.